7月1日到5日，全球共达成8项资产授权与合作交易。中国医药市场仅有1项国内交易。恒瑞医药与基石药业就后者的已上市药物阿伐替尼达成商业化合作，首付款500万美元。
国际市场上，7月份的首周共签署了7项资产授权与合作交易。其中最值得关注的交易是GSK与CureVac之间就后者的多项疫苗资产达成合作，首付款4.33亿美元，总金额15.68亿美元。
From July 1 to 5, a total of eight licensing and cooperation deals were sealed globally. In the China biotech sector, only one domestic deal was signed between CStone Pharmaceuticals and Hengrui Pharmaceuticals, featuring an upfront payment of $5 million for the approved asset, Avapritinib.
Globally, seven licensing and cooperation deals were sealed in the first week of July. The top deal of the week was the $1,568 million agreement between CureVac and GSK for multiple assets, with an upfront payment of $433 million.
2b. Global section
3. M&A Deals
4. Top Deals of the year 2024
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions. For more information, please visit www.yafocapital.com
Event Name: ACCESS CHINA Networking & Gathering @BIO
